Prostate Cancer


The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.

Trial overview


Prostate cancer


Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic.

Eligibility criteria

To be considered for the study you must meet the following criteria:

  • Metastatic prostate cancer with demonstrated resistance to standard ADT 
  • eGFR ≥ 40 mL/min/1.73 m2
  • Prostate cancer with significant neuroendocrine or sarcomatoid component 
  • Chemotherapy within previous two months
  • External beam radiotherapy within previous two months

Study details

The Enzalutamide-Enhanced Imaging study – is a Phase II study comparing the expression of prostate-specific membrane antigen (PSMA), before and after treatment with enzalutamide (Xtandi®)1, using positron emission tomography (PET). Forty Australian men with progressive metastatic castrate-resistant prostate cancer (mCRPC) who are about to receive second-line androgen-deprivation therapy with enzalutamide will be enrolled. Enzalutamide is believed to increase PSMA expression in some patients with prostate cancer and the goal of ENHANCING is to quantify this increase, to evaluate the potential of combining enzalutamide with PSMA-targeting radiopharmaceuticals for prostate cancer treatment.

Further information

For more information regarding this clinical trial click here.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.